ArticleNeuro-oncology2025

Advancing clinical response against glioblastoma: Evaluating SHP1705 CRY2 activator efficacy in preclinical models and safety in phase I trials.

Priscilla Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.